Arbuckle Stuart A Form 4 October 31, 2017

FORM 4

Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Arbuckle Stuart A

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

(Middle)

Symbol

(Check all applicable)

EVP\Chief Commercial Officer

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

VERTEX PHARMACEUTICALS

INC / MA [VRTX]

3. Date of Earliest Transaction

Director 10% Owner Other (specify X_ Officer (give title below)

(Month/Day/Year) C/O VERTEX 10/27/2017 **PHARMACEUTICALS**

INCORPORATED, 50 NORTHERN

(Street)

(First)

AVENUE

(Last)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

BOSTON, MA 02210

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	ion Date 2A. Deemed 3. 4. Securities Acqu y/Year) Execution Date, if Transaction Disposed of (D) any Code (Instr. 3, 4 and 5) (Month/Day/Year) (Instr. 8)			(D)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)		
Common Stock	10/27/2017		S <u>(1)</u>	4,165	D	\$ 141.41	116,952	D		
Common Stock	10/27/2017		M	2,125	A	\$ 96.87	119,077	D		
Common Stock	10/27/2017		S(1)	2,125	D	\$ 149	116,952	D		
Common Stock	10/31/2017		S(1)	11,617	D	\$ 142.18	105,335	D		

Edgar Filing: Arbuckle Stuart A - Form 4

					(2) (3)			
Common Stock	10/31/2017	S <u>(1)</u>	5,600	D	\$ 143.54 (3) (4)	99,735	D	
Common Stock	10/31/2017	S <u>(1)</u>	25,999	D	\$ 144.54 (3) (5)	73,736	D	
Common Stock	10/31/2017	S(1)	17,501	D	\$ 145.34 (3) (6)	56,235	D	
Common Stock	10/31/2017	S(1)	7,783	D	\$ 146.61 (3) (7)	48,452	D	
Common Stock	10/31/2017	S <u>(1)</u>	5,000	D	\$ 147.87 (3) (8)	43,452	D	
Common Stock	10/31/2017	S <u>(1)</u>	1,000	D	\$ 148.54 (3) (9)	42,452	D	
Common Stock	10/31/2017	S <u>(1)</u>	500	D	\$ 149.34	41,952	D	
Common Stock						140	I	401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
	\$ 96.87	10/27/2017	M	2,125	(10)	07/14/2024		2,125

De Sec (In

(9-02)

Stock Common Option Stock (Right to

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210

EVP\Chief Commercial Officer

Signatures

Buy)

/s/ Omar White, Attorney-in-Fact

10/31/2017

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a weighted average price of \$142.18 (range \$141.83 to \$142.74).
- (3) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (4) Open market sales reported on this line occurred at a weighted average price of \$143.54 (range \$143.03 to \$144.02).
- (5) Open market sales reported on this line occurred at a weighted average price of \$144.54 (range \$144.04 to \$145.01).
- (6) Open market sales reported on this line occurred at a weighted average price of \$145.34 (range \$145.05 to \$145.87).
- (7) Open market sales reported on this line occurred at a weighted average price of \$146.61 (range \$146.20 to \$147.18).
- (8) Open market sales reported on this line occurred at a weighted average price of \$147.87 (range \$147.22 to \$148.20).
- (9) Open market sales reported on this line occurred at a weighted average price of \$148.54 (range \$148.25 to \$149.18).
- (10) The option vests in 16 quarterly installments from 7/15/2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3